Nafamostat mesylate
Nafamostat mesylate, a synthetic serine protease inhibitor, that
contains antiviral and anti-cancer properties, used to treat acute
pancreatitis. It is apowerful MERS- inhibitor that obstructs membrane
fusion, was found inhibitive to 2019-nCoV infection when tested in EC50
= 22,50 μM, CC50 > 100 μM, SI> 4,44
concentration rate, suggested for further studies [10]. As per the
researchers at the University of Tokyo, Nafamostat will prevent the
fusion of the virus envelope with the host cell surface proteins, the
first step in infection with SARS-CoV-2 at one-tenth of the
concentration provided by Camostat mesylate (Foypan), which was recently
described by a German group as a SARS-CoV-2 inhibitor [39].